Literature DB >> 2653399

Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.

C A Hills1, L R Kelland, G Abel, J Siracky, A P Wilson, K R Harrap.   

Abstract

Ten human ovarian carcinoma cell lines have been studied as a potential in vitro screen for the development of novel anticancer platinum complexes. Lines have been established and developed both from solid and ascitic tumours, from pretreated and untreated patients, and are available at a range of in vitro passage numbers. The biological properties of the lines were consistent with them being human, epithelial and of ovarian carcinoma origin. Using a tritiated thymidine or leucine uptake method, and a 96 hour continuous drug exposure, the lines have been calibrated against four platinum-containing chemotherapeutic agents: cisplatin, iproplatin, carboplatin and tetraplatin. Striking differences in cytotoxicity were observed across the lines for each agent. Some lines were consistently resistant, others generally sensitive, whereas some showed clear evidence of differential sensitivity to a particular agent. Statistical analysis (Spearman rank correlation) involving the six possible pairings of drugs showed that cisplatin, iproplatin and carboplatin elicit a very similar pattern of response in these lines whereas tetraplatin elicits a completely different response pattern. Similar cytotoxicity values were obtained using a soft agar cloning assay. Results using a tetrazolium dye reduction assay, however, gave somewhat higher and more variable values, particularly with tetraplatin. The thymidine uptake assay will be adopted in further studies on a selected panel of six lines. This panel encompasses the spectra of sensitivities identified for each of the four agents against the original ten lines and may provide a useful screening facility for the development of novel platinum drugs, in that it detects both cell line-determined and structure-determined differences in cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2653399      PMCID: PMC2247140          DOI: 10.1038/bjc.1989.108

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Characterization of four new cell lines derived from human squamous carcinomas of the uterine cervix.

Authors:  L R Kelland; L Burgess; G G Steel
Journal:  Cancer Res       Date:  1987-09-15       Impact factor: 12.701

2.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

3.  Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient.

Authors:  C R Wolf; I P Hayward; S S Lawrie; K Buckton; M A McIntyre; D J Adams; A D Lewis; A R Scott; J F Smyth
Journal:  Int J Cancer       Date:  1987-06-15       Impact factor: 7.396

4.  Semiautomated colorimetric assay for in vitro screening of anticancer compounds.

Authors:  R L Ruben; R H Neubauer
Journal:  Cancer Treat Rep       Date:  1987-12

5.  Ovarian trials at the Royal Marsden.

Authors:  E Wiltshaw
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

6.  Initial assessment of tumor-associated antigen CA-125 in patients with ovarian, cervical, and testicular tumors.

Authors:  P K Buamah; C Cornell; A W Skillen; B M Cantwell; A L Harris
Journal:  Clin Chem       Date:  1987-07       Impact factor: 8.327

Review 7.  In vitro screening of new drugs and analogues--specificity and selectivity.

Authors:  B T Hill
Journal:  Cancer Treat Rev       Date:  1987-12       Impact factor: 12.111

8.  Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane.

Authors:  W K Anderson; D A Quagliato; R D Haugwitz; V L Narayanan; M K Wolpert-DeFilippes
Journal:  Cancer Treat Rep       Date:  1986-08

9.  Patterns of expression of a tumor associated antigen, defined by the monoclonal antibody HMFG2, in human epithelial ovarian carcinoma. Comparison with expression of the HMFG1, AUA1 and F36/22 antigens.

Authors:  B G Ward; D G Lowe; J H Shepherd
Journal:  Cancer       Date:  1987-08-15       Impact factor: 6.860

10.  A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity.

Authors:  P R Twentyman; M Luscombe
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

View more
  56 in total

1.  Genomic imbalances associated with acquired resistance to platinum analogues.

Authors:  B Leyland-Jones; L R Kelland; K R Harrap; L R Hiorns
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

2.  A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.

Authors:  Jian Zhang; Leiping Wang; Zhonghua Wang; Xichun Hu; Biyun Wang; Jun Cao; Fangfang Lv; Chunlei Zhen; Sheng Zhang; Zhimin Shao
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

3.  Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.

Authors:  L R Kelland; M Jones; G Abel; M Valenti; J Gwynne; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis.

Authors:  M J Gardner; J B Catterall; L M Jones; G A Turner
Journal:  Clin Exp Metastasis       Date:  1996-09       Impact factor: 5.150

5.  CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.

Authors:  Victoria E Anderson; Michael I Walton; Paul D Eve; Katherine J Boxall; Laurent Antoni; John J Caldwell; Wynne Aherne; Laurence H Pearl; Antony W Oliver; Ian Collins; Michelle D Garrett
Journal:  Cancer Res       Date:  2011-01-15       Impact factor: 12.701

6.  The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers.

Authors:  Elodie E Noel; Marc Yeste-Velasco; Xueying Mao; Jackie Perry; Sakunthala C Kudahetti; Ningfeng F Li; Swee Sharp; Tracy Chaplin; Liyan Xue; Alan McIntyre; Ling Shan; Thomas Powles; R Tim D Oliver; Bryan D Young; Janet Shipley; Daniel M Berney; Simon P Joel; Yong-Jie Lu
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

7.  Hyaluronic acid secreted by mesothelial cells: a natural barrier to ovarian cancer cell adhesion.

Authors:  L M Jones; M J Gardner; J B Catterall; G A Turner
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

8.  Platinum complexes with imino ethers or cyclic ligands mimicking imino ethers: synthesis, in vitro antitumour activity, and DNA interaction properties.

Authors:  Francesco P Intini; Angelina Boccarelli; Valentina C Francia; Concetta Pacifico; Maria F Sivo; Giovanni Natile; Domenico Giordano; Pietro De Rinaldis; Mauro Coluccia
Journal:  J Biol Inorg Chem       Date:  2004-07-06       Impact factor: 3.358

9.  Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; G Abel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Mechanistic basis for overcoming platinum resistance using copper chelating agents.

Authors:  Zheng D Liang; Yan Long; Wen-Bin Tsai; Siqing Fu; Razelle Kurzrock; Mihai Gagea-Iurascu; Fan Zhang; Helen H W Chen; Bryan T Hennessy; Gordon B Mills; Niramol Savaraj; Macus Tien Kuo
Journal:  Mol Cancer Ther       Date:  2012-08-21       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.